Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR").

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

Kodiak Sciences KOD announced that it has completed enrollment in a late-stage study of tarcocimab tedromer in patients with ...

NY Retina, a newly launched ophthalmology practice, is set to open March 20 in a newly purchased medical office building in ...

Kodiak Sciences (KOD) announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with ...

The study titled as ‘Mitigation of Lens Opacification by a functional food in a diabetic rodent model’, published in the ...

Motorists who need to wear glasses when driving could face a £1,000 fine and three points on their licence for ignoring ...

Hormonal changes can cause physiological and pathological changes in the eye, and eye care providers should monitor pregnant ...

REGENXBIO (NASDAQ:RGNX – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on ...

Terry Kim, MD, is a board-certified ophthalmologist, Chief Medical Officer at Alcon, and Professor of Ophthalmology at Duke ...